Endra Life Sciences granted extension to regain Nasdaq compliance

Endra Life Sciences announced that on August 27, 2024, the company was notified by The Nasdaq Stock Market LLC that the Nasdaq Hearings Panel has granted the company’s request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. To regain compliance with the bid price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading sessions on or before November 20, 2024. The company is considering all available options to timely evidence compliance with the terms of the Panel’s decision.